Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

Abstract: Systems and methods for distributing a filling fluid are discussed. More particularly an exemplary filling system may include a reservoir holding a filling fluid for distribution. The filling system may also include a pump and filling nozzle fluidly coupled to the reservoir. A processor executes a filling module that when executed receives at least one input fluid property of the filling fluid and generates at least one set of operating parameters for controlling operation of the pump during a filling operation based at least in part on the fluid property. The generated set of operating parameters enable control of the pump to distribute the filling fluid through the filling nozzle, such that a fluid interface with a stable resting profile forms in the filling fluid in the filling nozzle adjacent to the nozzle opening after the filling fluid is distributed from the filling nozzle.

Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.

Abstract: A method executed by an engine of a computing device is described. Login credentials are received by the engine from a user via a graphical user interface (GUI) of the computing device. The engine then queries a database to identify a user profile based on the login credentials and grants the user access to a cloud-based electronic signature platform. The user is prompted to upload a document. The engine receives an action from the user on a module of the cloud-based electronic signature platform and executes the action on the document. The module may be: an in-person signing module, a secure documentation module, an e-notarization module, a capture module, a secure documentation transmission module, a fingerprint recognition module, a retina recognition module, and/or a facial recognition module, among others.

Abstract: This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer.

Abstract: The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.

Abstract: A lighter, more cost-effective roofing system and method, which includes a rain diverting feature for directing rainwater and snowmelt away from an underlying sheet material and roof deck, is provided. The invention includes a sheet material having an upper surface and a lower surface. The upper surface includes one of a hook and loop fastener and the lower surface is configured to be attached to the roof deck. The present invention further includes a plurality of roofing tiles, each tile having hook and loop fasteners adhered to a back face which extend along the width of the tile at or near the uppermost and lowermost edges.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions.

Abstract: A method for producing 6-oxo-1,4,5,6-tetrahydropyridazine-3 -carboxylic acid is disclosed that includes steps of adding hydrazine sulfate with 2-ketoglutaric acid in a container as a solid, adding water to the solid creating a heterogenous mixture of the hydrazine sulfate, 2-ketoglutaric acid and water, blending the heterogenous mixture for at least one hour, and measuring the heterogenous mixture to confirm that it has converted into 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid. Hydrazine sulfate can be added to the 2-ketoglutaric acid in the container at a ratio of greater than 1.1. The compound 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (PCA) has many uses. It has been used for medical applications and as a building block and for medical applications. The compound is also a product of the remediation of hydrazine using 2-ketogluraric acid.

Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.

Abstract: Systems and methods for distributing a filling fluid are discussed. More particularly an exemplary filling system may include a reservoir holding a filling fluid for distribution. The filling system may also include a pump and filling nozzle fluidly coupled to the reservoir. A processor executes a filling module that when executed receives at least one input fluid property of the filling fluid and generates at least one set of operating parameters for controlling operation of the pump during a filling operation based at least in part on the fluid property. The generated set of operating parameters enable control of the pump to distribute the filling fluid through the filling nozzle, such that a fluid interface with a stable resting profile forms in the filling fluid in the filling nozzle adjacent to the nozzle opening after the filling fluid is distributed from the filling nozzle.

Abstract: Periodontal disorders such as disorders associated with a dental implant are treated with a laser where an average laser power along with other laser parameters provide particular settings for the treatment, the treatment including one or more of creating a gingival trough or flap around the implant, ablating or denaturing infected tissue via photothermolysis, lasing a pocket around the affected implant, and compressing marginal tissues against the implant.

Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Abstract: A breast milk collection and storage system is disclosed that comprises a manual breast pump. The manual breast pump comprises a breast cup configured to engage with a mother's breast. The breast cup comprises an opening. The manual breast pump also comprises a reservoir at a base of the breast cup configured to receive breast milk through the opening and collect breast milk extracted from the mother's breast. The breast milk collection and storage system also comprises a stopper configured to seal the opening to prevent leakage of breast milk from the reservoir. The breast milk collection and storage system further comprises a capsule configured to enclose the manual breast pump with the stopper and apply a compression force to the stopper to maintain the seal of the opening when the capsule is closed.

Abstract: A roofing system and method, which includes elongate rain diverting devices for directing rainwater and snowmelt away from an underlying sheet material and roof deck, is provided. The system includes roofing tiles having strips of hook and loop fasteners (H&L strips) adhered to both faces. The rain diverting devices have an H&L strip adhered along a lower edge of both faces. As each new row of tiles is installed on the roof deck, the device is applied over an upper portion of the tiles, extending over and onto the sheet material above the tiles, and across the roof deck. As additional rows of tiles are installed, each device is releasably attached to underlying and overlying tiles by way of the H&L strips adhered to both the tiles and the device. The devices also allow for single lap tiling (less weight on roof deck) and for use of shorter tiles (saving material cost).

Abstract: A medical device for percutaneous or venous access is provided with an internal cavity, from which a cannula extends in a first position of work. The cannula is supported by a distal end of a cannula-holder which is able to move within the cavity under the action of a resilient thrust element to a second position of work. Actuation means associated with the body of the device are provided to permit this movement and cooperate with actuation counter-means integral with the cannula-holder. In at least one of the two positions of work, the cannula has its longitudinal axis (W) disposed inclined relative to the longitudinal axis (K) of the tubular body.